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Lkrpitr substantial basic and ~linkal elti~rt~ toaddress the pmh- 
tern 0T rostenosis aLr wcutanwms coronary interrontion, elk- 
tire yreventiva therapi& have not yet been developed. Neverthe. 
less. the accumulated information hsr provided much insight into 
the prows of restesork in addition to allowing standards to be 
dewloped for adequale clinical trtals. 
The pathophysiotegy OFrestcnosis ncreasingly appears to be 
distinct from that ol prhnwy atherosetermtr. Restenosir nvolves 
elastic recoil. incorporation of thromhus into the lesion and 
fibrocellular proliferation in varying degrees in different pstierds. 
Lack of an animul model thal satisfactorily mimics restenosis i B 
mator Imucdlment to further understanding of the procas. Clin- 
icaistudik are hamprod bydifficultksin fi~dinga&teunifying 
definition of raten(lsts and by variable methods of reparling 
kdlow.up. Rqmtlng of clhUcal outcomes of all patients in angin. 
graphic nubstudies would allow a more satisfactory interpretation 
or the results olctinical trtats. Current nontnwsive test results arc 
not accurate nough to sublitute for angiographic and clinical 
outcome data in intervention trials. 
In the mqjorily al obwvnttonat studies, only diabetes and 
unstable angina bsve emerged PI const.slontly ax&ted with 
restenosis: whereas rnmt of the standard risk factors for athero. 
scl~rasts have a less constslenl relation. Dinppvintingly, the new 
athereftomy and tsxr trchnohtgks have not s&clod r&en& 
rates. The one poible exception is coronary stating, as a result 
al the larger tuminst diameter achieved by the ptvr~nent of the 
m&hanirai Wratlon al nlkmxlemlic vessels, attention to the 
prinriplos 01 tlhdcfd trials and obsrvrtbm are m@ed to detect 
the impact of risk factors and interventions M the multtfactorlal 
problem d reatmosts. Adequate sample sizes, mtkcttan of clhdcsl 
and an&graphic out- and fsclorirt stcdy dalgnr hotd 
promise for unraveting lhtb importPat IimitatIon ol prcutanwr 
intervention. 
(J Am Cofl Carditd 1991;17:28-138) 
The topic of restenosis after coronary angiop!asly has con- 
tinued to arouse great interest as the volume of interven- 
tional prucedures performed continues to increase. Recent 
data documeut an increase from IW.00.l ungioplusty proce- 
dures in 1985 to 3oO.Mx) in 1989. The addition of oewer 
technologies into the therapeutic armamentxium has further 
intensified the need 10 develop approaches ID reduce the 
occurrence of restenoris. Despite the tremendous amount of 
basic And clinical research addresssing. this problem. this 
overview must begin with the simple summary statement 
that an approach to reslenosis that is definitely proved to 
reduce its occurrence has not yet been developed. The 
remainder of this report focuses on a review of develop- 
ments in our understanding of the process of restenosis and 
the appmaches that may lead to a reduction in restenosis 
ra,es. 
Pathophysiology 
Unstable atherosclerotic plaque. Primary atherosclerotic 
plaque contains a complex mixture of smooth muscle cells, 
fibrous tissue and cholesterol. Restenotic lesions are much 
murc fibrous in nature. with few cholesterol pools. Despite 
rhe limitations of most previous studies examining the influ- 
ence of tradilionat risk lactors for athcmsclcrosis on resfe- 
nosis risk. only in the case of diabetes has a maior effect 
heen observed: However. increasing evidence is a&umula,- 
ine tha, the instabilitv of aneina relates closelv to the risk of 
ad&se events afte; angi&asty. implicating the unstable 
atherosclerotic plaque with accompanying thromhotic fat- 
tars as a mi\ior culpri,. This ditfcrence in plaque composition 
may also explain the wily of recurren, infarction as a 
presenting menifectadon of restenosis because myocardial 
infarction is generally believed ,o resul, from fissuring of an 
atherosclerotic plaque in an area overlyins a lipid pool c 11 change xn the dimensioas of the vessel lumen. Recent 
The fibrous nature of the reslenotic plaque may protect tt reports 17.8) illustrate the difficulties in using rradittonai or 
agatnnt rupture. visual methods of as~e~stnent. with significant overestima- 
Animal model of alberesckrmir. Unfortunately. a wt. lion of lesion severity by 15% to 25% ab compared with 
able animal model of restenosis caoable of simulaline. I~C auant~Iatwe methods. further obrcurinc the likelihood of 
human process has not been Found. Characlcnstacs if an detecting. real changes in vessels undergoing angioplasty. 
ideal animal model of atherosclerosis nclude the presence of These reports also suggest hat visual assessment 8s highly 
minimal genetic variability within the model. an ccc&rated inaccurdte in the midrange of diameter stenosis estimates 
time frame for the induction and development of lesions and (25% to 75% in which omcedurai success or failure is beine 
determined. histologic and morphologic similarity between the animal 
lesion and the complex human atherosclerotic plaque. Ad- 
ditional desirable features include anatomy that approxi- 
mates human arteries with regard to dimensions and config- 
uration. the capacity to withstand multiple procedures and 
low costs for feeding, instrumentation and management of 
the animal. Consistent development of high grade stettoses 
and occlusions has been limited to selected rabbit. swine and 
nonhuman primate models (2.3). Rabbit models. while eco- 
nomical, generally involve production of extreme hyperlipi- 
demia. with plaque histologic studies revealing foam cells 
with little fibrosis or calcification. The vearel caliber and 
distal vessel topology are also not suitable for testing inter- 
ventional strategies (4.5). Nonhuman primates can yield 
atherosclerotic lesions similar to human lesions. but are 
more difficult to manage. expensive to maintain and require 
prolonged induction and development time. Miniature and 
micro swine models have recently been developed for inter- 
ventional research. In the Yucatan micro swine. complex 
lesions resembling human plaques have developed aRer 
balloon denudation and a hyperchokstemlemic diet (6). 
However, wen this model has the drawbacks of Q high 
atttttion rate and lack of peripheral vascular access. and the 
model necessitates the study of peripheral rather than cow 
nary arteries. 
Standards for awss@ results oi angioplavty. In cvaluar- 
ing the results of angioplasty relative to other therapeutic 
alcrnaives and for developing clinically effective ap- 
proaches to the problem of rester&s. three measurements 
are helpful. 1) The severity of the stenosis before the 
procedure should be carefu’ty measured (constituting the 
baseline measurements. 2) Measurement of the degree of 
obstruction in the early wstorocedure period is essential 
(yicldmg the “acme &I?). Although a‘preliminary report 
from F.mury University (9) indicated that optimization of 
portangioplasty results had little impact on rcstenosis rates 
in a acne, of 2.444 patients. the follow-up angiogrdphic tale 
was 52%. leading to a substantial risk of statistical bias (see 
Statirtical Aooroachesl. Data from the M-HEART studv (10) 
sugger! that’abhougb &cedural success can be achie& 1; 
the overwhelming majority of patients, the desired egree of 
stenosis reduction will be realized in only 75% of the 
succe,sfol procedures. 
Rde of animal sludii. Given the inadequacies of each of 
these animal models, the decision to proceed from animal 
testing to human investigation remains difficult. The news- 
sity of developing safety and feasibility data from animal 
models is well recognized. but the choice of a particular 
model does not currently have a sound theoretic or practical 
base. A further difficult issue is whether success in one 
animal model is enough to justify human study or whether 
multiple animal models should be used. Currently, we be- 
lieve lhat animal studies are most useful to define the 
possibility that intimal proliferation can be impeded by a 
particular therapy, but that this type of study should not lcad 
to confidence that a similar result should he amicipated in 
complex human atherosclerotic platue. 
31 A preliminary report by Rensinl: ct al. 0 I) suggested 
that in addition to changer occurring over prolonged periods 
during follow-up. more immediate changes occur. They 
described the phenomenon whereby 50% of the theoretic 
maximal gain i;lost immediately after angiuplasty seconddry 
to elastic recoil of the vessel. This effect was most pro- 
nounced in the IeA anterior descending coronary arteryand 
was considered not to be due to coronary spasm. Therefore. 
the determination of the postprocedure result should be 
made after allowing a brief period for the process of elastic 
recoil to become evident. Finally. the result at a designated 
follow-up point 4 to 6 months after the procedure. when the 
remodeling process will be completed in the majority of 
patients. provides the critical comparative measure (thus 
determining long-:erm success or failure) 17.12). 
Reporting Restenosis Rates 
Objective qu;ntifintkm o( angioplssly results. In repon- 
ing the impact of a therapy on clinical outcome. both rhe 
minimal lumind diameter and the luminai diameter relative 
to the reference vessel diameter should be coupled with 
event rates. Alternatively. to evaluate therapies designed to 
prevent the anatomic orocess of restenosis, the difference 
beween the immedi& postangioplasty result and the 
follow-uo result should be auantilied usine an obiective 
The pioneering work oi Serruys et al. (7) has led to a measure such as videodensitometry or an automated edge- 
clearer understanding of the issues Involved in determming tracing device. Kaiblleisch et al. 113) compared the results of 
restenosis rates. Es%ntial to the development ofcomparable automated quantitative angiography with caliper measure- 
standards is the concept th;lt clinical outcome measures ments of percent diameter stenosis. They found that over- 
must be integrated with the measurement of absolute estimation of noncritical stenoses and underestimation of 
,ACC “0,. 17. Na 6 
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Figure 1. Exampler of four crws involving inter- 
venlional inrracoronary technology. The refer- 
ence .liametcr remains co”sta”t B13.2 mm for a,, 
examples. In example I, an immediate improve- 
ment in the minimal luminal diameter lMLDl of 
303% resuhs in a lumen of I .6 mm (50% diamewr 
stenosisl. A modest encroachment of 0.8 mm 
results in a % decrease in minimal luminal 
diameter and a significant residual xenods GW% 
diameter stenosis). In example 2. further en. 
croachment leads m a 75% decrease in minimal 
luminal diameter (88% diameter stenosis) and 
recurrent angina. Restenosis occurs in both cares 
with use of both definition (Def.) A (>$I% rte- 
nusis at follow-upl and definition B PO.72 mm 
decrease in minimal luminal diameter from post- 
prccedure to follow-up). In example 3. ao im- 
proved initial result (a f&l% improvement in 
minimal luminal diameter1 coupled with a similar 
dearee of encroachment durina the fottowu~ 
p&d as in example I res& in a mini&l 
tuminal diameter at follow-up of 1.6 mm (513% 
diameter stenosis). Restenosis OSSWE warding 
to dchnilion B. whereby a decrease ofO.8 mm in 
minimal luminal diameter is present. hot there is 
no resrenorisifdefinition A&used. Inexample4. 
initial excellent resutrs are maintained with the 
absence of rwenosis by either definition. 
critical stcnoocs occur frequently and that the measurements 
have poor overall reproducibility. The authors (13) coo- 
cluded that because the use of calipers does not overcome 
the limitations UC visual estimation of stenosis severity, rhis 
method cannot be recommended for clinical practice. 
Measurements required ioor definition of restenosir. Sev- 
eral examples arc given in Figure I, illustrating the difficulty 
in using a definition of restenosis based on differences in 
“percent stenosis” alone. These examples hold the refer- 
ence diameter constant for illustration purposes. In many 
cases. the reference diameter undergoes changes of similar 
magnitude to the minima! luminal diameter. The use of 
percent diameter stenosis then is dependent on two factors. 
varying independently and sometimes in opposite directions 
from each other, leading to an underestimation of the actual 
change in stenosis werity. To obviate these problems, we 
recommend that m addition to percent stenosis. absolute 
rncasurcmcnts should also he reported, either minimal lumi- 
nal diameter (mm) or cross-sectional arca (mm’). to describe 
changes in vessel dimensions when the procc~s of intimal 
proliferation is described. 
Variables for reporting results of angioplasty. On the 
basis of this though1 process. we suggest that the results of 
all intravascular interventional technologies b: reported in 
terms of three vartablcs. I) The clinical &comes bf death, 
myocardial inlarction. symptomatic angina and recurrence 
of ischemia as documented by functional testing for provok- 
able &hernia should he reported. 2) The anatomic result 
before treatment. immediately after treatment and at long- 
term follow-up should be ascertained. 3) The difference 
between the immediate and long-term results should he 
quantified to estimate the overall rcstenosis effect. This 
measure ideally should he adjusted for changes uccurring in 
the normal or reference portions of the vessel. 
Angiographic assesrrment of intimsl pmlifenlirm and pm- 
cedurnl success. Reiher et al. (14) have taken an important 
step forward by proposing a standard for a quantitative 
angiographic definition of intimal proliferation. They sug- 
gested that only changes >0.72 mm in minimal luminal 
diameter represent a “true” change in the vessel geometry. 
Thts finding was derived fmm mcaswemcot~ made at dis- 
parate times under basal conditions. demonstrating that 
0.72 mm represented twice the standard deviation of the 
difference of duplicate measurements. None of the patients 
in their study 114) underwent angioplasty before the mea 
surernerds. Other work by this group (IS) showed similar 
variability in the reference diameter (at I20 days, mean 
differences of -0.36 mm for the stenosis and -0.3C for the 
reference diameter), thus rendering the use of percent diam- 
eter stenosis somewhat questionable for the purpose of 
estimating the degree of intimal proliferation. The use of the 
preceding definition (change ~I.72 mm) avoids rcconcilia- 
tion of the dynamic changes occurring in the reference 
diameter (7). Despite the obvious limil&ons suggested by 
these observations. binary restenosis rates can he reported, 
although continuous mcawrements of the absolute change in 
vessel dimensions remain the most sensitive method of 
comparing different groups of patients. 
As noted previously. the data from which this quantita- 
tive reference standard was developed were acquired under 
basal conditions in patients who did not undergo coronary 
angioplasty before the measurements were obtained. Addi- 
lional stcdiec are needed to confirm ihe validity of thns 
approach and whether an interaction may exist between the 
use of absolute dimensions (mm or mm? and the ves)el 
dilated (for example, left anterior dewnding coronary ar- 
tery diagonal branches versus right coronary anery marginal 
branches) or the absolute size of the vessel II to 2 vs. 3 to 
4 mm). Detailed analyses of qualitative criteria of an&~ 
graphic appearance to define a succeasfol proccdore have 
not been conducted, but such analyses comparing the initial 
angiographic appearance with long-term outcome are essen- 
tial for understanding the detertninants of a s. xcssful beat- 
meat strategy. A further area of investigation is whether 
angiographic critel% alone are sufficient for declaring proce- 
dural success or whether demonstration of revewd of isch- 
emia or other metabolic abnormalities as determined bv 
techniques such as thallium-201 scintigmphic studies or 
positron emission tomography will be useful. Until the 
necessary anatomic and clinical variables have been identi- 
fied and standardized. the most relevant definition of re- 
stenosis will remain elusive. 
If a binary variable for restenosis is to be utilized. a useful 
construct is to evaluate the presence or absence of progrer- 
sion ofvessel encroachment usingdefinitions that exceed the 
error of the technique. Despite these intellectually appealing 
observations. a report by G&y et al. (16) provides disturb- 
ing documentation that additional standardization of me:h- 
c&logy is required. They reponed that reproducibility of 
quantitative angiography can be substantially altered by 
operator-dependent variables used in the identification and 
s&ection of-both the projection and the frame. 
Statistical Issues 
The issued random crmr: fak positive and false negative 
results. Inadequate attention to several important statistical 
issues has hampered progress in the investigation of bctors 
oiTecting restenosis and approaches to its prevention. One 
such issue is random error, which is essentially attributable 
to sampling variation, a factor strongly influenced by smdy 
design (for example, sample size) and statistical character- 
istics of the estimator (for example. variance). Two lypes of 
error can result from random sampling variation when 
making statistical inferences. First, the null hypothesis may 
be rejected when it is actually true. thus cauring a false 
positive study. Alternatively. the null hypalhesis may be 
accepted when the converse is true. leading to a false 
negative study. 
In studies of restenosis. sample Gzes for a particular 
outcotne are often inadequate. potentially leading to the 
incorrect premise of a negative study (type II error). Another 
possible problem occurs when multiple auistical compari- 
sons we made during the analysis ohase of a study. In tixs 
instance, any association found may be entirely due to 
chance, thus producing a false positive result (type : error). 
Methods of adjusting for this potential source of error 
include adjusting the required p value for significance (Bon- 
ferrnm correction). limitine comoarisons accordux to the 
“rule of 101” lone compa&on fir every IO end p&l or 
vakdauon of the study results in a second entirely mdepen- 
dent sample In parncular. validation in an independent 
sample provider significant strength for any association 
found. 
The issue cd diiierential rate of foikw-up and coronary 
angiographg. A major issue in wdies evaluatmg restenosis 
swats from differential raw of follow-up. If the chang,e in 
obatrucuon from the postprocedure &“I, to a follow-up 
study is the best measure of restenosis, then the tneawre- 
ment must be made at follow-up evaluation. Unfortunately. 
coronary angiography is not a procedure that can be per- 
formed on all patients after angioplasty for a combination of 
techmcal. medical. social and economic reasons. The drop. 
out of patientc from repeat angiography does not occur with 
equal frequency across the spectrum of symptom classes 
because patients without symptoms, with a presumably 
lower role of restenosis. are less likely to return for restudy. 
Patients who die. presumably with a higher restenosis rate. 
arc unable to re~rn. This problem. with selective and 
incomplete follow-up study. could be addressed on several 
levels to reduce statistical bias and increase the clinical 
relevance of re5ults. 
At the most basic level. the outcome of patients who do 
not return for coronary angiography can be classified in one 
of three ways. The patient’s outcome could be having 
restenosir or having no restenosis or the patient‘s data could 
be excluded from the analysis group. Occasionally. an effort 
is made to impmve the r&ull~ by carrying the process one 
step further and determining the symptomatic status of the 
patient at the time when angiography was scheduled. A 
common policy is to consider an asymptomatic patient as 
having no restenosis. Because the reported restenosis rate in 
asymptomatic patients is between IO% and 32% such an 
asoaption can lead to a systematic underestimation of the 
true restenosis rate. Conversely. excluding these patients 
altogether and using data from those patients followed up 
angiognphicslly only can lead to an overestimation of the 
true restenods rate. Similar problems should be recognized 
in the case of patients who die or have an intercurrent 
myocardial infarction withoa repeat angiograpky. Exclu- 
sion of these patients is likely to result in a systematic 
underestimation of the true restenosis rate. 
Addressing the pmbkm ofitteompkte angiographi follow- 
up. A superior method for estimating the true restenosis 
rate would be to categorize the patient as carefully as 
possible for the probability of restenosis based on available 
clinical factors. Thus, knowing the proportion of patients 
without follow-up angiography in each symptom class 
(a>vmptomatic. atypical or typical symptoms) and the reste- 
no& &c in the &ients u&going repeat angiography in 
each clas%. a. better estimate of the “true” restenosis rate for 
the patient% under study should be possible. 
We have used data from the Coronarv Arte~ Descriptors 
and Restenoris iCADRes) Project, a” ongoing project at 
Fiare L. The problem resullind from selccdve and incomplrle angio- 
graphic follow~p aoer angwplarty is demonrtrared in this family of 
cwws. Dala pramted hers were derived from the CAD,& popula- 
lmn in which 85% anomgraphe follow-up was obtained. in this study 
rhe overall resrenosis rare in parienrs followed up angiographically was 
379. Hawevcr. IO understand the effect ofarrumptiom made concern- 
ing patienlr without follow-up angiography. this observed overall rate 
\huuld be viewed asa weighted avemgeofthe rcsknosis rate obrewed 
far a~ympmmatie OlF, and tha, obscwcd l-or symptomatic ,4’S%, 
oaden,r:ibe considemblediRerence intbenetworate~emoba~ilerthe 
&brlantial vanation that can occur in overall resrenosis r&s depend- 
IMP an the urowdon of asvml)lomalrc and svm~mmanc Mients 
Duke Medical Center, to address this problem of incomplete 
angiographic follow-up study. The study group consists of a 
training smple of I.069 patients randomly selected from 
2.138 consecutive patients with a successful initial angio- 
plasty procedure. All patients undergoing coronary angio- 
plasty at Duke University were asked to return for repeat 
angiography at 6 manlhs unless a conlraindication was 
present or an intercurrent event occurred requiringcatheter- 
ization before the 6 month angiographic end point. This 
project has resulted in successful repeat angiagraphy in 85% 
of eligible patients. Ucing data from this group of patients. 
we were able to examine the effect of differential rates of 
angiographic follow-up study (Fig. 2). The reported resteno- 
sis rate can vary subslantially, depending ~)n how patients 
failing to return are included. We recommend using such 
adjuslment techniques to estimate the possible range of 
In example B il is assumed that 50% of the palients not followed 
up are symptomatic and 50% are asymptomalic. In this case, it is 
assumed that 50% ofthe padenls not followed up have the restenosis 
rate of 49% attributable to symplomatic patients and the remaining 
5O% have Ihe 31% rate of restenosis atrributable to symptomatic 
patients. Under these assumptions. the esdmated l”lrue”) overall 
restenosis rate for the entire group would be 39%: that is. the 
estimated overall restenosis rare = (IO.37 Y 0.401 + 10.49 x 0.301 + 
,0.31 x 0.301,. 
In examtie C it is assumed that IN% of p&ems no, followed 
up angiographically are asymptomatic. The patients without 
fallowup are then asrumed Lo have restenosis at the 31% rate 
artribulable to the asymptomatic padems. This results in an esd- 
maled l’Yrue”l overall reslenosis rate for the enlire group of 33%: 
that is, the estimated overall restenosis rate = IO.37 X 0.4ol + (0.31 
x OSAI,. 
Thu. in these three examples. despile the same observed re- 
stenosis rare (37%) in angiographically fallowed up patients. the 
estimated reslenosis rate for the entire group ranges from 33% to 
44%. depcndinpon the assumptions made about the padents wkhout 
an&graphic follow-up. 
ncranl restenosis rates. rather than simply relying on avail- 
able data. 
Noninvasive Testing 
The value of a noninvasive test that could accurately and 
reliably detect coronary restenosis is obvious. As just re- 
viewed. the reported value of a noninvasive test depends 
greatly on the completeness of angiographic follow-up data. 
Unfortunately. the results of noninvasive testing are fre- 
quently confounded by inadequate stress yielding low exer- 
cise heart rates, the presence of drugs that are known to 
influence test results and the extent of disease in vessels 
other than those dilated (17). 
Symptoms versus stress testing (Tables 1 and 2). The value 
of symptoms for detecting restenosis has varied widely 
among siudier. although on average 60% to 70% of patient\ 
with recurrent angina have restenosis and 10% to 20% ol 
those without recurrent symptoms lhave rcsreoosis (Table Il. 
Exercise treadmill testing substantially improves the detec- 
tion of restenosis. especially if information from the electro- 
cardiogram (KG) and symptomatic data are wnthesized 
(Table 21 (IWO). Radionuclide an&rapPy and exercne 
thallium studies have been reported 1%?9) to have hlpher 
specificity. although substantial problems with sensitwity 
remain. 
Several studies l23.26.30.31) have reported that an early 
thallium scintisraphy test with exercise. atrial pacing or 
dipyridamole c&heiect early in their course patients who 
will later have restenosis (Table 31. Exercise echocardroz- 
raphy and dipyridamole echocardiography are also used to 
detect restenosis (32-341. In a study 1321 of 71 patten~s who 
underwent exercise echocardiography nf the time of fol- 
low-up angiography. the sensitivity of a regional wall motion 
abnormality immediately after cxweiqe was 71%. the bpeci- 
ficity was 68% and the positive and ne@ive predictive 
values were 53% and 82%. rerpectivelv. 
Predictive value of noninvas& Ming. The role of nonm- 
vasive testing in the detectton of restenods bar not substan- 
tially changed over the past year. Although B positive te\t 
result is only moderately accurate in identifyint? patient* 
with angiogmphically defined restenow. a negative result 
provides a high level of assurance that re\lenosi\ is absent. 
The outcome of pattentc wth angiogmphic rrxt~no~~~ who 
rcma+~ symptomatic and who have no evidence of exerciw 
induced i\chemm is uncertain. although one preliminary 
report 1351 indicate5 a benign cottrse in the% pattents. with 
occurrence of symptoms well before a clinical event. There- 
fore. in clinical prdcticc “walchful waaing” untd symptv 
matic or erense-mnduced &hernia occurs appears IO be 
reaowble. 
Patient-Related Factors 
Patient-r&&d variables awxiated with rprtenosis. In a 
recent review and meto-analysis of available data 1361. we 
concluded that several patient-reMed vanables were appar- 
ently ;wociated with rentenosis. These bctors included 
male gender. continued smoking after angiopiasty. dlaberes. 
abxnce of a previous myocardial infarction and tinstable 
angina. Wsny other factors were found to have no associe- 
non with rrstenosis. Additional reports (37-39) over the pat 
year baw been inconsistent. leadinE to grearer uncertainty 
with regard to some risk facron and restenohis. Only dmbe- 
tes. severe angina and the absence of prior infarction have 
con\istemly remained as substantial patient-related varia 
ble, 137-39). 
Two recent studies t38.40). both from the Cleveland 
Clina. evaluated the associauon f multiple risk factors and 
reaenow lnlerpretation of these srudtes is hindered by low 
or unknown rates of angiographic follow-up (32.4% in one 
study and the use of only patients with angiographic fol- 
low-up in the other). Neither of these studies identified 
gender as a risk factor for restenosis. These findings are 
consistent with the hypothesis that previously reported 
higher restenosis rates m men may have represented inade- 
quate initial results in luminal reduction because of the 
inability of older angioplasty equipment to achieve a small 
residual stenosis in law coronarv arteries. 
Smoking. Continue2 smoking was not found to be related 
to restenosis in the Cleveland Clinic studies (38.40). therebv 
raising the issue of whether the previously reported smail 
series (41) pointing to continued smoking as a risk factor in 
fact were not representative of the general group of patients 
undergoing attgioplasty. This issue requires further evalua- 
tion in larger prospective studies. 
Hyperlipidemia. The effect of lipids on restenosis re- 
mains controversial. Berg&on et al. (42) found 1 substantial 
relation between multiple baseline lipid measures and the 
risk of restenosis, including total choleslerol high density 
lipoprotein (HDL.1. low density lipoprotein (LDLI. apolipo- 
proteins A, and B lapo-A, and B) and various ratios. Linear 
relations between restenosis rates and apo-A,. LDL and 
HDL were also found. In a separate study (431, higher serum 
liproprotein-a (Lp[al) levels zt follow-up were associated 
with restenosis. Several studies (40.43,44), however, found 
no relation between restenosis and lipid values at baseline or 
follow-up and one stud) 1441 actually reported a lower risk of 
restenosis in patients with higher total cholesterol levels. 
Fibrittolytic system variables and restenosis. Several small 
studies have now begun to investigate the relation between 
aspects of the fibrinolytic system and restenosis. In a study 
(45) of 106 patients. 36 of whom showed angiographic 
evidence of restenosis, an increase in plasminogen activator 
inhibitor-l levels was observed after angioplasty in patients 
with restenosis. whereas a decrease in plasminogen activator 
inhibitor-l from baseline values was observed in those 
without reslenosis. In a smaller study (46) of greater detail 
but limited by its retrospective design, elevation of almost 
every procoagulant factor (plasminogen activator inhibi. 
tar-I. tissue plasminogen activator antigen level. fibrinogen. 
factors VII and VIII) and depression ofinducible fibrinolytic 
response were observed in patients with restenosis. Several 
other small studies (47.48) demonstrated a release of mark- 
ers of white cell activation in patients undergoing angio- 
plasty. although no studies evaluating a possible relation to 
restettosis have been performed. 
Role of long&nt treatment with hemodialysis. Another 
small study (49) reported an extraotiinary restenosis rate of 
81% in I I of 17 patients on long-temt treatment with hemo- 
dialysis who returned for fallow-up angiography after under- 
going angioplasty. Whether this rate identifies dialysis itself 
as the primary risk factor or whether the associated melb 
bolic abnommlities are critical remains to be determined. 
In sswmary, surprisingly few factors have consistently 
been demonstrated to be associated with the risk of resteno- 
sis. The possibility remains that this finding represents an 
artifact of studies with inadequate measuretnent of risk 
factors and incomplete angiograpbic follow-up, although the 
evidence is increasing that the process of restenosis is 
distinct from thal of primary atherosclerosis (50). 
Lesion Morphology 
Morphologic predictors of restenosb. Results from the 
recentlv corn&ted M-HEART stud-, I101 orovide the onlv _ . 
new data with regard to lesion morphology and its effect on 
restenosis. Five covariates were found lo be independent 
predictors of restenosis in both univariate and multivariate 
analysis. These were stenosis location, baseline percent 
diameter stenosis. stenosis length, adjacent artery diameter 
and postangioplasty stenosis severity. The angiographic 
restudy rate of 73.5% combined with the sample size of the 
study (the highest of any pharmacologic intervention trial to 
date) allowed stratification of lesions into low. intermediate 
and high risk for restenosis. Unexpectedly. the lesions 
thought to be at lowest risk of restenosis tended to have a 
lower restenosis rate in the patients receiving methylpred- 
nisolone. 
Halon et al. (39) examined 90 patients with unstable 
angina undergoing coronary angioplasty for angiographic 
factors identifying patients at high ri,k for reslenosis. They 
found that restenosis was more frequent in the left anterior 
descending coronary artery. in patientr with multiple irreg- 
ularities. in the presence of diminished Thrombolysis in 
Myocardial Infarction (TIMI, Row (<grade 3) and in patients 
with evidence of intraluminal thrombus. The authors 139) 
concluded that although coronary angioplasty can be per- 
formed safely in patients with unstable angina. m patients 
with these risk factors. restenosis may be the rule rather than 
the exception. 
Implications. These data confirm the evolutionary phases 
that coronary angioplasty is undergoing with attempts to 
identify patients who would derive the most short-term 
(avoidance of pmceduml and in-hospital complications) and 
long-term (avoidance of restenasis) benefit from angioplasty. 
Carefully performed analyses of existing observational data 
bases using combined patient risk factor data and extensive 
acquisition of lesion morphology coupled with qwmtitative 
angiogmphy will lay the groundwork for future interven- 
tianal trials using modifications of either the procedure itself 
or administration of pharmacologic agents to modify cellular 
growth. 
New Angioplasty Technologies 
Over the past year, substantial information has accrued to 
Permit the development of an initial wrsoeclive on the role 
bf new technolo&es in approach& r&tenosis. Specific 
details concerning these technologies are provided else- 
where in this symposium. An overview will he provided 
here. 
Autoperlushm &vice. Prolonged. slow balloon inflation 
has teen associated with less restenosis in an animal model, 
prompting hope that either pretreatment with beta- 
adrenergic blockers. calcium channel blockers, nitrates. 
oxygenated fluorocarbons or retroperfusion or mechanical 
approaches to allow prolonged inflation would have an 
impact on k-stenosis. The development of an autoperfusion 
device has allowed a significantly extended balloon inflation. 
yielding a somewhat lower restenosis rate than that observed 
with standard angioplasty in a pilot study (51) of 67 patients 
with % angiographic follow-up. A multicenter andomized 
trial of I min versus I5 min inflations is currently underway. 
with the primary end points of immediate outcome and 
long-term restenosis. 
Atherectomy. This procedure provides *II im.,ortant po- 
tential appmach to restenosis because it works by physically 
removing the atherosclerotic plaque. often leaving a normal 
or nearly normal lumen, as visualized an&graphically at the 
completion of the interventional prc;c.iure. Furthermore. 
creation ofa more favorable rheologic environment featuring 
asmoother residual lumen with more normal Row character- 
istics might pmvide a further advantage in improving proce- 
dural success or reducing rcstenosis. However. in a recent 
report (SZ), 37 (4070) of 91 lesions developed restenosis after 
treatment wth the Simpson Atherwath. a device that re- 
cently gained approval for use in tte treatment of coronary 
ancry disease. Similar esults hove been observed (531 in 
>70 patients returnine for 6 mordh follow-uo anrioaraohv 
after. atherectomy with the Transluodnai E&&t;o~- 
Endartereciomv Catheter ITECI. T&e results occurred 
despite the typ&d creation of a widely parent lumen during 
the procedure. pointi% to the probability that vascular 
injury overwhelms any local rheologic effect that would 
reduce restenosis. 
coronary dent tmptanwtion. Coronary stents also pro- 
duce a widely patent hr _ry in the immediate periprocedural 
interval. Unfonunateiy. preliminary data (54) indicate a 
sahstantial restenosis rate with all available stents. although 
home reponed data (55) suggest that when the final stem 
diameter is >3.2 him and a single steot is used (as opposed 
to multiple unplan:ationsL restenosis may be somewhat 
diminished. Careful evaluation is consistent with the concept 
that stem implantation can eliminate the elastic recoil com- 
ponent and that with the same degree of intimal prolifera- 
tion. th.- lumen can remain widely patent in a patient after 
Gent placement. In cowas:. a significant residual stenosis 
would be present after angioplasty because of the lesser 
residual lumen at the end of the procedure. Further an& 
graphic follow-up study is needed to clarify this ;ssue. 
taserangtopkxsiy. Restenosis data after laser angioplas~y 
are preliminary at this time, but the small amount of infor- 
mation concerning thermal use of laser devices as a way to 
prevent restenosis is not encouraging. Another approach. 
laser balloon angioplasty (56). appears beneficial in reducing 
awe procedural failure, hot the restenosis rate appears not 
to be alfected by this technology (57). More recently, truly 
ablative laser systems have been developed using clinically 
powerful pulsed lasers, allowing the possibility for direct 
tissue ablation without pathologic beating of surrounding 
tissue. 
In xamnmry, the interventional mechanical approaches to 
coronary afiery disease are evolving rapidly. Preliminary 
data suggest hat even though tissue removal. stenting and 
laser ablation may have specialized applicability. these tech- 
nique, do not overcome the proliferative respwise responsi- 
ble for restenosis. Further studies with randomized compar- 
isons are needed to assess the proper role of each of these 
new technologies. 
Clinical Trials 
Antiptatetet ~gtts. The use of antiplatelet agents and the 
modulation of prostaglandis production have been a major 
emphasis of pharmacologic restenosis trials to date. Aspirin 
has been tested in seven clinical trials (58-64). hut in only 
one study (59) was the result evaluated by quantitative 
anaiographv. When data from four clinical trials (58-61) 
were combined in a meta-analysis format (65). there was an 
insignificant 11% reduction in the risk of restenosis with 
aspirin (Fig. 31. When three trials (62-64) comparing high 
Figure 3. Overview ol m816 eompvring aspirin lherapg with placebo 
or conml groups for restenosis after an&pkwy. Results are shown 
as odd, r&m wth 95% rvnfidcncc intervals. as cakulalcd by 
Mantel-Hacn~zcl bltitibtics. An adds ratio < I is indicative of a lower 
rcstenosis rate among the waled pauenls compared with placebo. 
treated or control pauenls. A statirhcally rigaficant Ip < O.OSl lower 
reste.osis rate is seen in (hole studies where the 95% confidence 
Y..:cr Jr do not cross the vertical tine to& ratio = I) Oddr ratios 
aI ilwlicatc b htghcr rcstcnwi? iate among the lreaicd palirnlr. 
Odds ratios were calculated from parvats 10 whom angiographic 
documentation of restenosis were available. In those studies where 
angiographic data were not reported the overall numbrn were used. 
Data an from Ohman et al. (651. Thornton et al. (58). White et al. 
159). Schwartz et al. (60) and Finci et al. 161). 
Figure 5. Overview of trials comparing omega.3 fatty acids with 
placebo for restenosis after ang~optasly. ttesultr are shown as adds 
ratio with 95% confidence interwb. Patients randomized to fish oils 
received 3 to 6 dday of omega-3 fatty acids. See Figure 3 for 
description of methods. Data are from Ohman et al. (651, Dehmer et 
al. (73). Grigg et al. 1741. Milner et al. (751. Reis et al. (76) and Slack 
et 81. (77). 
Prnslscyclin and snticwgulanks. Two relatively small 
studies K&69) evaluated prostacyclin analogues and demon- 
strated a substantial trend toward benefit. A marked reduc- 
tion in negative clinical end points was observed with 
ciprostene, although only a trend toward a lower rate of 
angiographically defined restenosis was observed (36). An- 
and low dose aspirin were combined, a trend tw .rd a lower ticoagulants have also been a source of recent interest. Both 
restenosis rate with low dose aspirin was present in two intravenous heparin and Caumadin (warfarin) were evalu- 
studies (62.631 (Fig. 41. In a recent study by Chesebm et al. ared in relatively small trials (58.70) with low rates of 
(661. no difference in minimal luminal diameter was found angiographic follow-up and neither agent demonstrated an 
amung patients randomized to aspirin (975 mglday) or pla- effect against restenosis. 
cebo. Ticlapidine was evaluated in one study (59) with no 
Coronary vasodilatorx and corttwsteroirJs. Vasndilators 
apparent individual effect. but when combined with nic- are generally administered to patients close to the time 
orandil (a calcium channel an?agonistl a significant reduction angioplasty is performed because of angiographic and clini- 
was observed in the rate of restenosis compared with that cal evidence of the importance of opasm as a complicating 
during aspirin therapy (67). factor of anpioplasty. Results of two studies (71.72) with a 
calcium channel antagonist were negative, although both 
studies included <3W patients. Because of the documented 
Figure 4. Overview of trials comparing high dose tl.uOD to 
ISW me/day1 and low do= (80 to 320 &day) arpirin in #he 
prevention of restenosis aRer an&pkwy. Resuks are shown as 
adds ratio wth 95% confidence intervats. See Figure 3 for descrip- 
tion of methods. Dlta are from Ohman et al. (651. Mufson et at. 1621. 
Schanzenbachcr et al. (631 and Dyckmans e! al. lfdl. 
importance of smooth muscle cell proliferation in the pro- 
cess of restenosis. interest has intensified in the potential use 
of antimitogens. The M-HEART Study Group (IO) recently 
reported on 915 patients randomly allocated to receive 
methylprednisolone (I g before angioplasty) or placebo. A 
restenosis rate of 3% was observed in the treated patients 
compared with 40% in the placebo group. although a retm- 
spective analysis suggested a beneficial effect of conicoste- 
raids in patients with low risk angiographic characteristics 
for rcstenosis. 
Fish oil preparations. The effects of fish oil preparations 
were examined in five studies (73-77). prompted by docu- 
mentation of antiaggregatory properties on platelets, favor- 
able alteration of lipid profiles and antimitogenic properties. 
Although two (73.75) of the five studies individually showed 
positive results. when the 725 patients involved in all the 
studies were evaluated as a combined group (65). an insig- 
nificmn treatment effect was found (Fig. 5). The possible role 
of fish oil is complicated by ditTcrcnces of opm~on regarding 
dose, timing and type of patient. so that no definitwe 
conclusion can be drawn at this time. 
Serum cholesterol reduction. Two recent studies (78.79) 
attempted to address the potential effect of cholesterol 
reduction on restenoris. In one study (78). 157 patients were 
randomly assigned to lovastattn therapy (20 to 40 mgidayl or 
to a control group. Respective restenosis rates of I?% and 
47% were found in the groups. This study was limited by 
only 50% awiocraphic follow-up. which was skewed toward 
the lovastatin group 163% ver& 37%). In a separate study 
(79) with 93% angiogmphic follow-up. 55 patients were 
placed on a die!. low&din +I0 to 80 mgldayl and colestipol 
(IO mglday) to lower cholesterol. A 34q restenosis rate was 
observed. which was not different from prewously reported 
historic control results. despite a reduction in total choles- 
terol from 221 to 131 mgidl over the course of the 6 month 
follow-up period. With the divergent results of these two 
studies, it is unclear whether efforts at lowering cholesterol 
have any effect on restenosis. 
Implications. Despite the extensive theoretic basis for 
the prevention of restenrsis. no triols have yet demonstrated 
a convincing effect. Many of the previous trials have been 
flawed by statistical and design problems. but multiple trials 
are currently underway to as~ss ench of !b? major area of 
potential impact. These trials provide an opportunity to 
resolve the pathophysiologic questions because most have 
an adequate planned sample size and extensive data collec- 
tion including qualitative and quantitative angiogaphy. 
Future Projections 
Clinkal trial approaches. The next year will see a prabf- 
eration of basic and clini-xl approaches to coronary resteno- 
sis. Because of the lack of B suittable animal model for 
restenosis. prevention of intimal proliferation in one species 
cannot he assumed to predict successful prevention of 
restenosis in humans. Development ofa successful approach 
to the prevention of restenosis will depend on careful cm~ 
piric clinical experimentation. attention to the details of 
measurement variables equated wit!! resteoosis. as well ar 
fastidious attention to study de.lgn. Outcome should be 
reported with respect to lw!n clinical and angiographtc 
results because no sin& defnition of restenoais is suitable. 
Relatively small. carefully ,:one studies with serial quantita- 
tive angiapraphic measurements will provide :he bat infor- 
mation about the impact of therapy on the processes of 
re,tenosis (elastic rrcoil and intimal proliferation). Larger 
clinical trials with measurcroents of less precise pathoana- 
tomic outcomes will he needed to ttssess the impact of the 
treatment as it pertains to clinical practice. One attractive 
approach, given the large number of anfioplasty procedures 
currently performed. would be to perform a “megatrial” 
with ascertainment of a composite clinical outcome. We see 
these clinical trial approaches as complementary. 
End points to characterize sngioptasty outcome. One ma- 
jor problem v;;th clinical trials involving resteo&s is the 
smAl number of “hard” clinical wents (death and reinfarc- 
fionl that occur in patients undergoing angioplasty. We 1801 
developed an apprcach to this oroblem in the area of acute 
myocardnl infarction. in which negative clinical outcomes 
are ranked and considered in the aggregate as a composite 
clinical end point. Clinicians can readily rank a similar set of 
end points characterizing angioplasty &tcom~ in the follow- 
ing order: death. stroke. nonfatal myoardial infarction. 
abrupt reclosure of the dilated Avery without myocardial 
Infarction. emergency coronary bypass surgery within 24 h 
of ang~oplasty, bypass surgery >?4 h after angiopla-y. 
recurrent sngioa. exercise-induced silent ischemia and an- 
gioFaphrally dwumemed restenosis without ~ympt~\ms or 
enercire-induced objectively documented ischcmia. If pa- 
tients are ranked according to the severity of these out- 
comes. a sensitive treatment comparinon can be made in a 
clinically relevant maotter. 
Factorial de&n to evaluate rest&s of treatment. Because 
the pathophysiology of restenosis is likely to Q multifacto- 
rial. the maximal eflicacy probably will be derived from 
combining Mtiple treatment approaches simultaneously. 
each attacking B different aspect of the pathophysiology. 
One possible scenario is that mechanical approaches will 
reduce restenosis by 2G%, antithrombin agentr by 2CN and 
antiplatelet agents by 1tY% Accordingly. cli&al trials 
should Ideally be designed using a factorial design. For 
example. B mechanical approach designed to prevent elastic 
recoil could be combined with an antithrombotic agent or an 
antiplatelet agent could k combined with an aotiprolifera- 
tive agent. Such a factorial design enables the study to 
evaluate both the individual and the combined effect of each 
approach. while avoiding the increawd overhead cost of 
starting two concurrent or sequential trials. 
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